An acquisition of Jennerex Inc. by Sillajen Inc. may be needed redemption for Jennerex’s recently troubled cancer immunotherapy, Pexa-Vec. The product failed to reach its primary endpoint of overall survival in a Phase IIb trial in September, resulting in a stock plummet for Jennerex’s European partner, Transgene SA.